Applied DNA Sciences, EvviVax announce cancer vaccine data

2021 02 17 17 07 0976 Dog Paw Hand 400

Applied DNA Sciences and its development partner EvviVax this week announced preclinical data published in the Journal of Experimental & Clinical Cancer Research concerning the use of Applied DNA's LinearDNA polymerase chain reaction (PCR)-based manufacturing platform to produce veterinary DNA cancer vaccines.

The firms noted that the study, published on June 6, found that two LinearDNA therapeutic cancer vaccines elicited a strong immune and specific antitumor response in mouse models using electro-gene-transfer as the delivery method.

Applied DNA said it intends to launch an initial clinical trial this year to validate the telomerase reverse transcriptase (TERT) cancer vaccine for canine B-cell lymphoma in conjunction with a lipid nanoparticle-based delivery system.

Page 1 of 9
Next Page